SPRB earnings date and last-quarter result: next report 2026-08-13, last quarter beat, P/E -1.19. Updated 2026-07-23.
Spruce Biosciences (SPRB) Research Hub
Spruce Biosciences (SPRB) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 43.99 USD (-2.57%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.19, market cap 0.06B. This hub links to the full technical, earnings and options research available for SPRB.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 43.99 USD (-2.57%) |
| 52-week range | 38.15 USD – 64.5 USD |
| Trend regime | Range |
| 14-day RSI | 52.7 (Neutral) |
| Trailing P/E | -1.19 |
| Market cap | 0.06B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-13 |
Available research for SPRB
Covered Call on SPRB: how it works, illustrative setup around the real 43.99 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on SPRB: how it works, illustrative setup around the real 43.99 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on SPRB: how it works, illustrative setup around the real 43.99 USD price, max profit/loss, breakeven and when to use it. Educational.
SPRB technical analysis: range, last 43.99 USD, RSI 52.7, 52w range 38.15 USD–64.5 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is SPRB in?
Spruce Biosciences (SPRB) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is SPRB in an uptrend or downtrend?
As of 2026-10-26, SPRB is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is SPRB's trailing P/E ratio?
SPRB's trailing P/E is -1.19, with a market cap of 0.06B. See the earnings research page for full valuation detail.
When does SPRB next report earnings?
SPRB is next scheduled to report earnings on 2026-08-13.